Advokatfirman Lindahl advises Intervacc AB (publ), listed on Nasdaq First North in connection with its rights issue of approximately MSEK 61.
The board of directors of Intervacc has resolved to increase the company’s share capital through an issue of shares with preferential rights for existing shareholders. The rights issue is subject to the approval by an extraordinary general meeting to be held on 9 March 2018. Upon full subscription of the rights issue, Intervacc will receive approximately MSEK 61, before deduction of transaction costs. The rights issue is guaranteed to an amount corresponding to approximately 80 per cent of the rights issue by guarantee commitments. The rights issue is carried out in order to enable Intervacc to further develop from being primarily a research and development company with Strangvac® as the main product, into a commercial production phase with a wide portfolio of vaccine development projects and to continue building a strong sales and marketing organisation.
Intervacc is a Swedish company within the biotechnology sector. The company’s main object is to develop modern sub-unit vaccines against economically important bacterial infections, mainly within animal health. The company’s vaccine candidates are based on several years of research at the Karolinska Institute and the Swedish University of Agricultural Research where the foundation was laid for the company’s research and development work.
Advokatfirman Lindahl assists Intervacc in the transaction with client relationship partner Per Hedman (Life Science) and partner in charge of the project Maria Arnoldsson (Capital Markets and public M&A), Anton Knifström, Oliver Kronberg and Mimi Hörnmo (Capital Markets and public M&A), Anders Burén (Life Science), and Anna Romell Stenmark, Isabella Rosman and Åsa Fahlén (Tax).